To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

H.R. 1843 would amend federal drug law to increase transparency in how the FDA reviews generic drug applications. Under this bill, the FDA would be required to inform generic drug manufacturers, upon request or during the review process, whether their proposed drug is qualitatively and quantitatively identical to the corresponding brand-name drug. If the drugs are not the same, the FDA would need to explain the reasons for the differences.

Additionally, the bill would require the FDA to update or publish guidance documents explaining how it makes these determinations about drug equivalence. If enacted, this could help generic drug manufacturers better understand FDA standards and potentially speed up the approval process. For consumers, clearer FDA guidance might eventually lead to more generic drug options reaching the market, which could help increase competition and potentially lower medication costs. The bill is currently in committee and has not yet been voted on by the full House.